Indapta Therapeutics Secures 22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
| FACTX Fund | USD 57.61 0.09 0.16% |
Slightly above 56% of Fidelity Advisor's investor base is looking to short. The analysis of overall sentiment of trading Fidelity Advisor Health mutual fund suggests that many investors are alarmed at this time. Fidelity Advisor's investing sentiment can be driven by a variety of factors including economic data, Fidelity Advisor's earnings reports, geopolitical events, and overall market trends.
Fidelity |
HOUSTON SEATTLE, December 17, 2024--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation cell therapies for the treatment of cancer and autoimmune diseases, announced today it has closed a 22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer cell therapy. Current investors RA Capital Management, LP, Leaps by Bayer, the impact investment arm of Bayer AG, Vertex Ven
Read at finance.yahoo.com
 |
Fidelity Advisor Fundamental Analysis
We analyze Fidelity Advisor's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fidelity Advisor using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fidelity Advisor based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Fidelity Advisor is currently under evaluation in price to sales among similar funds. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Fidelity Advisor Health Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fidelity Advisor mutual fund to make a market-neutral strategy. Peer analysis of Fidelity Advisor could also be used in its relative valuation, which is a method of valuing Fidelity Advisor by comparing valuation metrics with similar companies.
Peers
Fidelity Advisor Related Equities
| 70082LAB3 | 70082LAB3 | 2.51 | ||||
| FSELX | Fidelity Select | 0.95 | ||||
| VIASP | Via Renewables | 0.94 | ||||
| FSCSX | Software | 0.78 | ||||
| MSTSX | Morningstar Unconstrained | 0.56 | ||||
| RRTLX | T Rowe | 0.25 | ||||
| LBHIX | Thrivent High | 0.24 |
Other Information on Investing in Fidelity Mutual Fund
Fidelity Advisor financial ratios help investors to determine whether Fidelity Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fidelity with respect to the benefits of owning Fidelity Advisor security.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |